Format

Send to

Choose Destination
J Clin Microbiol. 2019 Aug 21. pii: JCM.00886-19. doi: 10.1128/JCM.00886-19. [Epub ahead of print]

Multicenter clinical evaluation of a novel multiplex real-time PCR (qPCR) assay for detection of fluoroquinolone resistance in Mycoplasma genitalium.

Author information

1
Microbiology Department, Vall d'Hebron University Hospital, Universitat Autònoma de Barcelona, Barcelona, Spain.
2
SpeeDx Pty Ltd, Sydney, Australia.
3
Centre for Women's Infectious Diseases, The Royal Women's Hospital, Parkville, Victoria, Australia.
4
Murdoch Children's Research Institute, Parkville, Victoria, Australia.
5
Central Clinical School, Monash University, Melbourne, Australia.
6
Melbourne Sexual Health Centre, Alfred Health, Melbourne, Australia.
7
Department of Obstetrics and Gynaecology, University of Melbourne, Parkville, Victoria, Australia.
8
Statens Serum Institut, Copenhagen, Denmark.
9
Microbiology Department, Vall d'Hebron University Hospital, Universitat Autònoma de Barcelona, Barcelona, Spain. mespasa@tauli.cat.
10
Microbiology Department, Corporació Sanitària Parc Taulí, Universitat Autònoma de Barcelona, Barcelona, Spain.

Abstract

Mycoplasma genitalium is a common sexually transmitted infection with a marked propensity to develop antimicrobial resistance. As few treatment options exist, this poses significant challenges to clinicians. Recent diagnostic advances have resulted in tests that report the simultaneous detection of M. genitalium and any resistance to macrolides, the first line treatment. This allows for therapy to be tailored to the individual, thereby optimizing treatment outcomes. However, resistance to fluoroquinolones, the second line treatment, is increasing in M. genitalium In this study, we describe a new assay, MG+parC (beta), which simultaneously reports the detection of M. genitalium and five parC mutations that have been associated with resistance to fluoroquinolones. These mutations affect the amino acid sequence of ParC at residues S83R (A247C), S83I (G248T), D87N (G259A), D87Y (G259T) and D87H (G259C). The study tested the MG+parC (beta) with 202 M. genitalium-positive clinical samples from Australia (n=141) and Spain (n=61). Compared to Sanger sequencing, the assay performed with a kappa value of 0.985 (95% CI, 0.955-1.000), with a mutation detection sensitivity of 97.6% (95% CI, 87.4-99.9), and specificity of 100.0% (95% CI, 97.7-100.0). Fluoroquinolone resistance-associated mutations in parC targeted by the assay were more prevalent among the Australian cohort (23.4% [95% CI, 16.3-31.8]) compared to the Spanish population (8.8% [95% CI, 2.9%-19.3%]), p = 0.019. The MG+parC (beta) kit is a simple and reliable method for simultaneous detection of M. genitalium and fluoroquinolone resistance-associated mutations in clinical settings. This novel diagnostic tool may extend the utility of the second line of antimicrobial therapies in M. genitalium infection.

PMID:
31434719
DOI:
10.1128/JCM.00886-19
Free full text

Supplemental Content

Full text links

Icon for HighWire
Loading ...
Support Center